Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31

Rhea-AI Summary

Glaukos (NYSE: GKOS), specializing in ophthalmic pharmaceuticals and medical technology, will release its second quarter 2024 financial results after market close on Wednesday, July 31, 2024. The announcement will be discussed by company management during a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET).

Access to the live webcast will be available on the company's investor relations website. Interested parties can join the conference call by dialing 888-210-2212 (U.S.) or 646-960-0390 (International) with the Conference ID 7935742. A replay will be available on Glaukos' website after the call.

Positive

• Scheduled release of Q2 2024 financial results on July 31, 2024, will provide insights into recent company performance.
• Management's conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results may indicate transparency and investor engagement.

Negative

• None.

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2024 financial results after the market close on Wednesday, July 31, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 31, 2024.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710585809/en/

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When will Glaukos release its second quarter 2024 financial results?

Glaukos will release its Q2 2024 financial results after market close on July 31, 2024.

What time is Glaukos' conference call on July 31, 2024?

The conference call is scheduled for 1:30 p.m. PT (4:30 p.m. ET) on July 31, 2024.

How can I join Glaukos' Q2 2024 earnings conference call?

To join the call, dial 888-210-2212 (U.S.) or 646-960-0390 (International) and use Conference ID 7935742.

Where can I access the live webcast for Glaukos' Q2 2024 financial results?

The live webcast will be available on Glaukos' investor relations website at http://investors.glaukos.com.

Will there be a replay available for Glaukos' Q2 2024 earnings call?

Yes, a replay will be archived on the company's website following the completion of the call.